Acinar Cell Carcinoma (ACC) in a Patient with Hypoglycemia: A Case Report

Hmaideh Akbari1, Arash Rezaei Shahmirzadi2, Hamed Jafarpour3, Morteza Fazlekhoda4, Ali Davoodi5
Seyed Arad Moselmaghili1

1Golestan University of Medical Sciences, Gorgan, Iran
2Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
3Student Research Committee, Mazandarn University of Medical Sciences, Sari, Iran
4Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran

INTRODUCTION

Pancreatic acinar cell carcinoma is one of the rare conditions of the gastrointestinal tract (1, 2). Although acinar cells predominate in the normal pancreas, their malignant transformation is rare, representing 1–2% of malignant pancreatic tumors (3). Although considered as a single tumor entity, acinar cell carcinomas (ACCs) vary in their morphological and clinicopathological characteristics (4).

Presenting signs and symptoms are usually nonspecific and may include abdominal pain, weight loss, nausea, and vomiting. Jaundice is an uncommon presenting sign in 0-21% of Patients (5-7). Acute pancreatitis is the presentation in about 13% of cases (5), but is less frequently acknowledged in retrospective case series. Lipase hypersecretion syndrome, a paraneoplastic syndrome of pancreatic tumors, is one of the rarest disease presentations described in 0-16% of cases (4, 5, 8). Metastasis is detected in about 50% of cases at the time of diagnosis and is most commonly found in the liver and regional lymph nodes (2, 4, 5). Endogenous hyperinsulinism can occur in some conditions, including; a beta cell secretion stimulant, such as a sulfonylurea, a beta cell tumor, a functional beta cell disorder, Insulin autoimmune hypoglycemia (9). But as far as we know, hypoglycemia is a rare presentation of ACC. So, here we report Acinar Cell Carcinoma (ACC) in old man with Hypoglycemia.

ABSTRACT

Pancreatic acinar cell carcinoma is one of the rare conditions of the gastrointestinal tract. Here we report Acinar Cell Carcinoma (ACC) in an old man with Hypoglycemia. The patient was a 79-year-old man with history of seizure. In lab data, Blood Sugar was 40 mg/dl and Brain problems were ruled out. For the last 2 to 3 months, he had spells shaky, sweaty, and weak; past medical history (PMH): Low grade Transitional cell carcinoma (TCC) and Diabetes mellitus (DM): negative. The prognosis for patients with mixed acinar-neuroendocrine carcinoma did not differ from that for those with histologically pure pancreatic ACC.

Key Words: Acinar cell carcinoma, seizure

Received: 09.22.2018

CASE REPORT

The patient was a 79-year-old man with history of seizure. In lab data, Blood Sugar was 40 mg/dl. Brain problems were ruled out. For the last 2 to 3 months, he had spells shaky, sweaty, and weak; past medical history, he had Low grade TCC, DM and DH were not detected. None of the family members had DM. Physical examination in this case including BMI=27 Kg/m2 (no changes in body weight changes), BP=130/70 mmHg, PR=85 beats/min, revealed as normal. Regarding the fasting test, patient showed neuroglycopenic signs and symptoms within 2 hours.

Laboratory findings showed that Urine sulfonylureas was negative and in abdominal CT scan, No mass was found. Pancreatic tissue was atrophic with normal contour. There was a 5mm round hypocholic mass lesion with rim around it in mid body of pancreas without any regional LAP. PD was about 3.3, 1.9 and 1 mm in head, body and tail respectively. Common bile duct (CBD) was about 6 and 5mm in mid and distal parts respectively and contained no sludge or stone.

Ampulla, Celiac trunk, Left liver lobe and Cystic duct was Normal. Also gallbladder had normal wall thickness and contained multiple small stones and sludge. The patient s blood sugar is then controlled after surgery and did not sign and symptom of hypoglycemia. In the case of established laboratory criteria, this lesion is mostly Insulinoma. Pathological examinations were performed in this study.

Accepted: 05.06.2019

ÖZET

Pankreas asiner hücreli karsinom, gastrointestinal sisteminin nadir durumlarından birdir. Burada hipoglisemili yaşlı bir erkekte Asiner Hücreli Karsinomunu (ACC) sunuyoruz. Hasta, 79 yaşında, nöbet öyküsü olan bir erkekti. Laboratuar verilerinde kan şekerinin 40 mg/dl idi ve beyin sorunları ekarte edildi. Son 2-3 ay boyunca, titrek, terli ve zayıf nöbetleri vardı; öyküsünde düşük dereceli transizyonel hücreli kanser, Diabetes mellitus ise negatifti. Miks asiner-nöroendokrin karsinomması olan hastalar için prognoz, histolojik olarak saf pankreas ACC’si olanlardan farklıdır.

Anahtar Sözcükler: Asiner hücreli karsinom, nöbet

Geçiş Tarihi: 22.09.2018

Kabul Tarihi: 06.05.2019
cases 5-year survival rate is 36–72%.

Also, in this patient, the amount of insulin, C-peptide, Blood Sugar 120 minutes after fasting, Cortisol, TSH, Hemoglobin, Creatinine, Sodium and Potassium were measured, as shown in Table 1.

Table 1: Some laboratory findings in patient

| Variable       | Level       |
|----------------|-------------|
| Insulin        | 25 lu/ml    |
| C-peptide      | 5.93 ng/ml  |
| Blood Sugar(120 minutes after fasting) | 20 mg/dl |
| Cortisol       | 198 ng/ml   |
| TSH            | 1.89 mIU/L  |
| Hemoglobin     | 13 g/dl     |
| Creatinine     | 1.4 mg/dl   |
| Sodium         | 140 mEq/l   |
| Potassium (K)  | 3.7 mEq/l   |

### DISCUSSION

Pancreatic acinar cell carcinoma (ACC) is a very rare pancreatic exocrine cancer. It accrue in 1% of pancreatic tumors in adults and 15% in pediatric subjects. They may show different clinical symptoms at presentation, morphological features, outcomes, and molecular alteration. The average age 59 years old (range 20–88 years). Male/female ratio of 2:1, ACC may arise in any portion of the pancreas. Average tumor diameter of 8–10 cm, well circumscribed, and at least partially encapsulated. Invasion through the capsule is a common finding and in about 50% of cases infiltration of the duodenum, large vessels, stomach, kidney, peritoneum, or spleen. Endocrine manifestations of ACC are Hypoglycemia secondary to tumor secretion of insulin and insulin-like growth factors. The diagnostic hallmark of ACC is IHC of acinar-specific products such as: trypsin, chymotrypsin, lipase, amylase, and carboxyl ester lipase (CEL). Histological Variant of ACC are Mixed acinar-neuroendocrine carcinomas, Acinar cell cystadenocarcinoma, Mixed acinar-neuroendocrine-ductal carcinoma, Mixed acinar-ductal adenocarcinoma. It’s extremely difficult to distinguish pure acinar cell neoplasm from mixed acinar-endocrine neoplasms based on morphology alone. Neoplasms exhibiting >25% of both cell types should be designated mixed acinar-endocrine neoplasms (10-12).

The molecular mechanisms involved in ACC pathogenesis and progression are largely unknown. Unlike ductal adenocarcinomas, typical mutations in KRAS, DPC4, p16, and TP53 genes are absent or very rare in ACCs. Pathogenesis mechanism includes abnormalities in the APC/β-catenin pathway. There is some morphological similarities between ACCs and NETs, so the differential diagnosis with NETs may be difficult. High-mitotic index, abundant necrosis, clearly evident nucleoli in apparently well to moderately differentiated cells, abundant eosinophilic cytoplasm, should give rise to the suspicion of an ACC. IHC must be used with caution. The use of general NET markers, chromogranin A and synaptophysin alone may be risky because ACCs show at least scattered NE cells, in 30% of cases, are particularly abundant (12-16).

Treatment includes Surgery which has metastatic, neutral invasion. In these cases 5-year survival rate is 36–72%.

We observed a high recurrence rate of 56.3 % in resected ones, including both local and distant metastases despite the well-circumscribed local confinement, ACC remains aggressive in nature overall median survival of 19 months. Factors related to a poor prognosis in pancreatic ACC in patients with resected tumor are Elder age, Large tumor size (>6.5 cm), Lymph node metastasis, Positive resection margin, Poorly differentiated tumors, Advanced tumor stage. (The prognosis for patients with mixed acinar–neuroendocrine carcinoma did not differ from that for those with histologically pure pancreatic ACC) (12-14, 17).

### Conflict of interest

No conflict of interest was declared by the authors.

### REFERENCES

1. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillehoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. Journal of Gastrointestinal Surgery. 2008;12(12):2078.
2. Wang Y, Wang S, Zhou X, Zhou H, Cui Y, Li Q, et al. Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. World Journal of Surgical oncology. 2016;14(1):172.
3. Klimstra DS. Nontubular neoplasms of the pancreas. Modern pathology. 2007;20:594-5112.
4. Tian L, Lv X-F, Dong J, Zhou J, Zhang Y, Xi S-Y, et al. Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. International journal of clinical and experimental medicine. 2015;8(9):14846.
5. Raman SP, Hruban RH, Cameron JL, Wolfgang CL, Kawamoto S, Fishman EK. Acinar cell carcinoma of the pancreas: computed tomography features—a study of 15 patients. Abdominal imaging. 2013;38(1):137-43.
6. Hsu M-Y, Pan K-T, Chu S-Y, Hung C-F, Wu R-C, Tseng J-H. CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations. Clinical radiology. 2010;65(3):223-9.
7. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schlicker RD, et al. Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. Journal of Gastrointestinal Surgery. 2008;12(6):1061-7.
8. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. Journal of clinical oncology. 2002;20(24):4673-8.
9. Garber AJ, Abrahamsson MJ, Barzilay JJ, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American association of clinical endocrinologists and the American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2017 executive summary. Endocrine Practice. 2017;23(2):207-38.
10. Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. European Journal of Endocrinology. 2014 Apr;170(4):R147-57.
11. Tian L, Lv X-F, Dong J, Zhou J, Zhang Y, Xi SY, Zhang R, Xie CM. Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. International journal of clinical and experimental medicine. 2015;8(9):14846.
12. La Rosa S, Sessa F, Capella C. Acinar cell carcinoma of the pancreas: overview of clinicopathologic features and insights into the molecular pathology. Frontiers in medicine. 2015 Jun;12:41.
13. Wang Q, Wang X, Guo R, Li G. A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in chinese patients. OncoTargets and therapy. 2016;9:5475.
14. Yoneda M, Kanayama K, Imai H, Shiraishi T. Report of a case of acinar cell carcinoma with its differential diagnosis on endoscopic ultrasound-guided fine-needle aspiration cytology. Journal of Cytology/Indian Academy of Cytologists. 2014 Apr;31(2):93.
15. Wang HL, Kim CJ, Koo J, Zhou W, Choi EK, Arcega R, Chen ZE, Wang H, Zhang L, Lin F. Practical immunohistochemistry in neoplastic pathology of the gastrointestinal tract, liver, biliary tract, and pancreas. Archives of pathology & laboratory medicine. 2017 Sep;141(9):1155-80.
16. See S, Yoo C, Kim KP, Ryoo BY, Chang HM, Hong SM, et al. Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. Journal of digestive diseases. 2017.